Estella Tembe Fokunang¹, Marceline Djuidje Ngounoue², Marie Therese Obama Ondoua³, and Charles Fokunang^1*

¹Department of Pharmacotoxicology and Pharmacokinetic, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon
²Department of Biochemistry, Faculty of Science, University of Yaoundé 1, Cameroon
³Department of Pediatrics, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Cameroon

*Corresponding Author: Charles Fokunang, Professor, Department of Pharmacotoxicology and Pharmacokinetic, Faculty of Medicine and Biomedical Sci- ences, University of Yaoundé 1, Cameroon.

Received: July 03, 2026; Published: August 11, 2026

The goal of clinical research is to develop generalizable knowledge that improves human health or enhances an understanding the human system. Volunteers who participate in clinical research facilitate the pooling of data that make it possible to secure an understanding of human biology/functioning. The odyssey a new drug or treatment for safety and efficacy, good quality is through clinical testing on patient volunteers. However, creating cohort with some volunteers on placebo with more risk of harm for the good of others is a big challenge demonstrates that clinical research has the potential to exploit patient volunteers. The ethical guidelines in place today were primarily a response to past abuses, the most notorious of which in America was an experiment in Tuskegee, Alabama, in which treatment was withheld from 400 African American men with syphilis so that scientists could study the course of the disease. Various ethical guidelines were developed in the 20th century in response to such studies. The purpose of this review is to exploit the ethical guidelines developed to protect patient volunteers and to preserve the integrity of the science in clinical research.

Keywords: Ethics; Clinical Research; Public Health

References

1. Lang TA., et al. “Clinical Research in Resource-Limited Settings: Enhancing Research Capacity and Working Together to Make Trials Less Complicated”. PLOS Neglected Tropical Diseases6 (2010): e619.
2. Hua Zheng., et al. “World Health Organization. Guidance for best practices for clinical trials”. Geneva (2024).
3. Manfrin A., et al. “Analysis of 4616 clinical trial initial submissions received by the Medicines and Healthcare products Regulatory Agency between February 2019 and October 2023”. British Journal of Clinical Pharmacology (2025).
4. Drain PK., et al. “Global migration of clinical research during the era of trial registration”. PLoS One 13 (2018).
5. Taylor-Robinson SD., et al. “Why is there a paucity of clinical trials in Africa?” QJM 114 (2021): 357-358.
6. Rodríguez-Feria P and Cuervo LG. “Progress in trial registration in Latin America and the Caribbean, 2007-2013”. Rev Panam Salud Publica (2017): 41.
7. D’Arcy HP. “A change in scientific approach: From alternation to randomised allocation in clinical trials in the 1940s”. BMJ 319 (1999): 572-583.
8. Gössling G., et al. “Current Scenario of Clinical Cancer Research in Latin America and the Caribbean”. Current Oncology 30 (2023): 653-662.
9. Park JJH., et al. “Urgently seeking efficiency and sustainability of clinical trials in global health”. Lancet Global Health 9 (2021): e681-690.
10. HEDPAC: advancing clinical trials capacity in Africa and the Caribbean regions. (2025).
11. Anand SS., et al. “Designing inclusive clinical trials: how researchers can drive change to improve diversity”. BMJ 388 (2025).
12. Anand SS., et al. “Inclusive research: a path to equity and better outcomes”. BMJ 388 (2025).
13. Clark J. “The war on equality”. BMJ 388 (2025).
14. Domingo-Fernández D., et al. “Natural Products Have Increased Rates of Clinical Trial Success throughout the Drug Development Process”. Journal of Natural Products 87 (2024): 1844-51.
15. Vujicic T and Cohall D. “Knowledge, Attitudes and Practices on the Use of Botanical Medicines in a Rural Caribbean Territory”. Frontiers in Pharmacology 12 (2021).
16. Kirigia JM., et al. “Status of national research bioethics committees in the WHO African region”. BMC Medical Ethics 6 (2005).
17. Mahase E. “Aid cuts threaten decades of progress in reducing child deaths and stillbirths, warns UN”. BMJ 388 (2025).
18. Fokunang CN., et al. “Artificial Intelligence in Medical Research: Ethical and Regulatory Challenges in Developing Economies”. Journal of Advances in Medical and Pharmaceutical Sciences 27 (6 (2025): 63-89.
19. Tembe-Fokunang Estella., et al. “Ethical Challenges in Conducting Clinical Trials for New Chemical Entities”. Journal of Clinical Epidemiology and Toxicology2 (2025): 2-6.
20. Fokunang CN., et al. “Ethical and Regulatory Challenges for Contract Research Organizations Conducting (Outsourced) Clinical Research in Sub-Saharan Africa with a Case Study of Cameroon”. Journal of Advances in Medical and Pharmaceutical Sciences4 (2025): 54-80.
21. Agbor MA., et al. “Pharmacovigilance: application and challenges for odontostomatology health practice in Cameroon”. European Journal of Pharmaceutical and Medical Research10 (2025): 04-15.
22. ZINTCHEM R., et al. “Generative Artificial Intelligence and the Learning of Clinical Nursing Reasoning: A Scoping Review, Proposal of a “Socioconnectrist” Approach”. ReAScI N°2 (2025).
23. Hume M and Abraham M. “Practical research ethics in Psychiatrics clinical trials. A guide for investigators”. Psychiatric Clinics of North America4 (2021): 549-561.
24. Bosnjak PM., et al. “Clinical trials in developing countries. Ethical considerations”. Psychiatria Danubina3 (2018): 285-291.
25. Emanuel EJ., et al. “What makes clinical research ethical?” JAMA 24-31;283 (20 (2020): 2701-2711.
26. Reid AM., et al. “Ethical dilemmas and reflexivity in qualitative research”. Perspective Medical Education2 (2018): 69-75.
27. Lo B and Parham L. “Ethical issues in stem cell research”. Endocrine Review3 (2009): 204-213.
28. Meurman JHJ. “Ethics in Research: Still an issue”. Dental Research11 (2016): 1205-1206.
29. Modi N. “Consent and the continuing evolution of clinical research ethics”. Archives of Disease in Childhood: Fetal and Neonatal Edition3 (2021): 230-231.
30. Koyfman SA and Yom SS. “Clinical research ethics: Consideration for the radiation Oncologist”. International Journal of Radiation Oncology, Biology, Physics 2 (2017): 259-264.
31. Redman BK. “Review of measurement instruments in clinical and research ethics, 1999-2003”. Journal of Medical Ethics3 (2006): 153-156.
32. Carter B., et al. “Why are there so few ethics consults in Children’s hospital?” HEC Forum2 (2018): 91-102.
33. Wendler D and Rid A. “In Defense of a social value requirement for clinical research”. Bioethics2 (2017): 77-86.
34. O'Mathúna D. “Research ethics in the context of humanitarian emergencies”. Journal of Evidence-Based Medicine1 (2015): 31-35.
35. Porter KM., et al. “The emergence of clinical research ethics consultation collaborative repository group”. American Journal of Bioethics1 (2018): 39-45.
36. Mahuli AV., et al. “Institutional ethics committee regulations and current updates in India”. Contemporary Dental Practice 8 (2017): 738-741.
37. Borysowski J., et al. “Ethics review in compassionate use”. BMC Medicine1 (2017): 136.
38. Barnbaum DR. “Supererogation in clinical research”. Medicine, Health Care and Philosophy3 (2008): 343-349.
39. Grady CK. “Bioethics in the oversight of clinical research: Institutional review boards and data and safety monitoring boards”. Institutional Ethics Journal 29 (1 (2019): 33-49.
40. Shaw D. “The quest for clarity in research integrity a conceptual schema”. Science and Engineering Ethics4 (2019): 1085-1093.
41. Meulenbergs TV., et al. “The current state of clinical ethics and healthcare ethics committees in Belgium”. Medical Ethics6 (2005): 318-321.
42. Parker MJ. “Scaling ethics up and down: moral craft in clinical genetics and in global health research”. Medical Ethics1 (2015): 134-137.
43. Lantos JD. “The Belmont Report and innovative clinical research”. Perspectives in Biology and Medicine2 (2020): 389-400.
44. Wenner DM. “Barriers to effective deliberation in clinical research oversight”. HEC Forum3 (2016): 245-259.
45. Bhola P., et al. “Ethical dilemmas experienced by clinical psychology trainee therapists”. Indian Journal of Medical Ethics4 (2015): 206-212.
46. McCullough LB. “Philosophical provocation: The Lifeblood of clinical ethics”. Journal of Medicine and Philosophy 1 (2017): 1-6.
47. Førde R and Hansen TW. “Do organizational and clinical ethics in a hospital setting need different venues”. HEC Forum2 (2014): 147-58.
48. Angell M. “Industry sponsored clinical research: a broken system”. Journal of the American Medical Association 80 (2008): 899-904.
49. Appelbaum PS., et al. “Therapeutic misconception in clinical research: frequency and risk factors”. IRB: Ethics and Human Research 26 (2004): 1-8.
50. Beecher HK. “Ethics and clinical research”. New England Journal of Medicine 274 (1966): 1354-1360.
51. Caldwell PHY., et al. “Clinical trials in children”. Lancet 364 (2004): 803-811.
52. Department of Health and Human Services. Code of Federal Regulations: Title 45 (Public Welfare). Part 46: protection of human subjects (45 CFR 46). US Government Printing Office (2005).
53. Featherstone K and Donovan JL. “Why don’t they just tell me straight, why allocate it? The struggle to make sense of participating in a randomized controlled trial”. Social Science and Medicine 55 (2002): 709-719.
54. Field MJ and RE Behrman. “The Ethical Conduct of Clinical Research Involving Children”. Washington DC: National Academies Press (2004).
55. Flory J and Ezekiel E. “Interventions to improve research participants’ understanding in informed consent for research: A systematic review”. Journal of the American Medical Association 292 (2004): 1593-1601.
56. Joseph Millum., et al. “The Ethics of Placebo-controlled Trials: Methodological Justifications”. Contemporary Clinical Trials 36 (2 (2013).
57. Nial Wheate. “The ethics of using placebos, World Economic Forum Nov 7, 2014, University of Sydney”.
58. Grigis A., et al. “Vulnerability in research ethics: A systematic review of policy guidelines and documents. PLoS One7 (2025): e0327086.
59. Welch MJ., et al. “The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials”. Clinical Trials 12 (5 (2015): 503-510.
60. Farooq AR., et al. “Ethical Challenges and Strategies in Conducting Research with Vulnerable Populations in Low and Middle-Income Countries”. Narrative Review Production and Hosting by KEMU (2025).

Citation

Citation: Charles Fokunang. et al. “The Ethics in Clinical Scientific Research: A Global Challenge in Public Health Dynamics in Low Resource Limited Countries". Acta Scientific Medical Sciences 10.9 (2026): 13-30.

Copyright

Copyright: © 2026 Charles Fokunang. et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.